ICLUSIG (ponatinib) CP-CML
and Ph+ ALL patient profiles

*National Comprehensive Cancer Network® (NCCN®) treatment guidelines for certain patients with T315I mutation, and it’s the only TKI with no known contraindicated BCR::ABL1 mutations.

Chronic-phase CML patient profiles

Individual results may vary

ROBERT: Experiencing resistance in chronic-phase CML with a T315I mutation

Man smiling while looking off camera.

MEET ROBERT
Presenting with rising BCR::ABL1IS levels after his first TKI therapy

Robert is a 55-year-old engineer who wants to regain control of his disease to maintain his career and family life. After losing response to a 2nd-generation TKI, recent labs show the development of a T315I mutation, prompting him to consider a treatment option that addresses resistance.

Robert’s treatment journey

1. At Presentation

""

Loss of response to 2nd-generation TKI after originally being in remission

  • PCR testing showed rising BCR::ABL1IS
  • Mutation testing revealed Robert was T315I mutation positive BCR::ABL1IS

 

Treatment history

  • First-line 2nd-generation TKI
    • Originally under control and in remission
    • Rising BCR::ABL1IS indicates a loss of molecular response

 

Laboratory results

  • BCR::ABL1IS is rising and is now 6.4%, despite adherence to 2nd-generation TKI
  • T315I mutation detected

2. Treatment Choice

""

Began second-line treatment with ICLUSIG 45 mg

  • Looking to regain durable and deep disease control*

3. Early Response

""

Robert achieved his early response milestones

  • BCR::ABL1IS down to 0.8% by MONTH 3
  • Used a response-based dose-reduction approach consistent with the OPTIC* trial design (dose reduced to 15 mg after achieving ≤1% BCR::ABL1IS)1
  • Slight rise in blood pressure was managed medically with no new arterial events

Conclusion

Why Robert’s physician recommends ICLUSIG

After developing resistance to a 2nd-generation TKI, Robert underwent BCR::ABL1 mutation testing and was found to be T315I-positive. Robert and his oncologists selected ponatinib (ICLUSIG) because it is recommended as a treatment option by the National Comprehensive Cancer Network® (NCCN®) treatment guidelines for certain patients with T315I mutation, and it’s the only TKI with no known contraindicated BCR::ABL1 mutations.1-4

Robert and his oncologist selected ICLUSIG because it is the only TKI with no known contraindicated BCAR::ABL1 mutations and is recommended as a treatment option by the NCCN treatment guidelines for certain patients with T315I mutation.1-4
*OPTIC is an open-label, multicenter, randomized study designed to evaluate ICLUSIG across multiple response-based dosing regimens for patients with CP-CML.1,2 A total of 282 patient received ICLUSIG and were divided into 3 cohorts: The first cohort (n=94) received a starting dose of 45 mg, the second (n=94) received a starting dose of 30 mg, and the third (n=94) received a starting dose of 15 mg. Patient in cohorts 1 and 2 were reduced to 15 mg daily upon achievement of ≤1% BCR::ABL1IS. The primary endpoint for OPTIC was ≤1% BCR::ABL1IS at 12 months.2,5
BCR::ABL1IS=BCR::ABL1 International Scale; CP-CML=chronic phase chronic myeloid leukemia; PCR=polymerase chain reaction; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor.

View ICLUSIG efficacy data for CP-CML

View ICLUSIG safety data for CP-CML


NAOMI: Chronic-phase CML with a suboptimal molecular response due to her intolerance with a second TKI

Woman looking off camera into the distance.

MEET NAOMI
BCR::ABL1 remains above target,
despite TKI cycling

Naomi is 62 years old, retired, and an active member of the community. She cycled through two 2nd-generation TKIs. Despite continuing treatment with a second-line TKI, she is experiencing interruptions in her treatment.

Naomi’s treatment journey

1. At Presentation

""

Naomi was treated with a first-line 2nd-generation TKI but lost response by 12 months

  • Initially reached ≤1% BCR::ABL1IS
  • At 12 months, her BCR::ABL1IS was 5.6%


Treatment history

  • Prior failure on first-line first generation TKI
  • Intolerance to second-line 2nd-generation TKI
    • Interruptions in treatment
    • Discontinued 2nd-generation TKI due to pleural effusions
  • Disease was not under optimal control


Laboratory results

  • BCR::ABL1IS was 2.1% 6 months after starting 2nd-generation TKI

2. Treatment Choice

""

Began treatment with second-line 2nd-generation TKI

  • Experienced pleural effusions and treatment interruptions
  • Discontinued at 6 months, having never reached ≤1% BCR::ABL1IS
  • BCR::ABL1IS at 6 months was 2.1%

Began treatment with 3L ICLUSIG

3. Early Response

""

Naomi achieved her early response milestones
 

  • BCR::ABL1IS down to 0.7% by MONTH 6
  • Used a response-based dose-reduction approach consistent with the OPTIC* trial design (dose was reduced to 15 mg after achieving ≤1% BCR::ABL1IS)1
  • Treatment is generally well-tolerated with no new safety events

Conclusion

Why Naomi’s physician recommends ICLUSIG

Because Naomi was intolerant to her 2nd-generation TKI, she and her physician agreed that ICLUSIG may be able to deliver deep, durable responses with manageable tolerability to help her achieve optimal disease control.*

 Due to her intolerance and prior loss of response to a 2nd-generation TKI, her physician recommended ICLUSIG, a 3rd-generation TKI, for the potential of a deeper response and achieving disease control.1,5*
*OPTIC is an open-label, multicenter, randomized study designed to evaluate ICLUSIG across multiple response-based dosing regimens for patients with CP-CML.1,2 A total of 282 patient received ICLUSIG and were divided into 3 cohorts: The first cohort (n=94) received a starting dose of 45 mg, the second (n=94) received a starting dose of 30 mg, and the third (n=94) received a starting dose of 15 mg. Patient in cohorts 1 and 2 were reduced to 15 mg daily upon achievement of ≤1% BCR::ABL1IS. The primary endpoint for OPTIC was ≤1% BCR::ABL1IS at 12 months.2,5

3L=third-line; BCR::ABL1IS=BCR::ABL1 International Scale; CP-CML=chronic phase chronic myeloid leukemia; TKI=tyrosine kinase inhibitor.

View ICLUSIG efficacy data for CP-CML

View ICLUSIG safety data for CP-CML

Ph+ ALL patient profiles

Individual results may vary

JOHN: A newly diagnosed patient with Ph+ ALL, otherwise healthy

Man sitting on a bench looking off camera.

MEET JOHN
Presenting with high bone marrow blasts, but no contraindicated comorbidities

John is 48, an active father and working professional with
a full calendar—school drop-offs, kids’ activities, and the
hobbies that keep him feeling like himself. With so much
depending on him, he wants a treatment option that has a
meaningful response.

John’s treatment journey

1. At Presentation

""

John, an otherwise healthy adult, was diagnosed with Ph+ ALL

Laboratory results

  • Bone marrow blasts 78%
  • BCR::ABL1/ABL1 (p190) 78%
  • Blood pressure considered in normal range, no medication
  • A1c 5.5%, no medication

2. Treatment Choice

""

Began first-line regimen with ICLUSIG 30 mg + chemotherapy

  • Targeting early molecular clearance

3. Early Response

""

John achieved his early response milestones

  • MRD-negative CR after induction (3 months)*
  • BCR::ABL1/ABL1 <0.01% by PCR after Cycle 2 (~8 weeks)
  • Therapy was generally well-tolerated with abdominal pain actively monitored and managed without resulting in ICLUSIG discontinuation

Conclusion

Why John’s physician recommends ICLUSIG

John and his physician are focused on maximizing his chance of long-term survival by achieving a durable remission. Their priority is a significantly superior rate of first-line disease control, shown by early MRD negativity, and a response with no contraindicated mutations or need for a stem cell transplant.1,2

After sharing decision-making with his oncologist, they chose ICLUSIG in combination with chemotherapy for the chance of a response.
*Dose was reduced to 15 mg upon achievement of MRD-negative CR after Cycle 2.

A1C=glycated hemoglobin; BCR::ABL1/ABL11IS=BCR::ABL1 International Scale; CR=complete response; MRD=minimal residual disease; PCR=polymerase chain reaction; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; WBC=white blood cell.

View ICLUSIG efficacy data for Ph+ ALL

View ICLUSIG safety data for Ph+ ALL


SARAH: A newly diagnosed patient with Ph+ ALL with comorbidities

Woman sitting at a kitchen table looking off camera.

MEET SARAH
Presenting with hypertension and diabetes, both managed by medication

Sarah is 63 years old, a retired teacher in a rural community who stays active through local events and social groups. Despite managing type 2 diabetes and hypertension, she remains generally fit and engaged, and is proud of maintaining her independence and role in the community. With her new Ph+ ALL diagnosis, she worries about how treatment may affect her ability to stay involved and live the life she values.

Sarah’s treatment journey

1. At Presentation

""

Sarah was managing type 2 diabetes and hypertension when she was newly diagnosed with Ph+ ALL


Comorbidities

  • Type 2 diabetes (controlled, metformin)
  • Hypertension (controlled, ACE inhibitor)


Laboratory results

  • Bone marrow blasts 62%
  • BCR::ABL1/ABL1 (p190) 64%
  • WBC 21x10

2. Treatment Choice

""

Began first-line regimen with ICLUSIG + chemotherapy

  • Targeting MRD-negative CR by the end of the induction period (~3 months)6

3. Early Response

""

Sarah achieved her early response milestones

  • MRD negative by CR at end of induction (3 months)
  • Increased blood pressure was managed with medication dose adjustment and did not result in discontinuation of ICLUSIG

Conclusion

Why Sarah’s physician recommends ICLUSIG

Given her comorbidities, Sarah and her oncologist are prioritizing a regimen with a manageable safety profile that still offers a chance at remission. Considering the disease’s agressive nature, they need an option that can be delivered in a community setting and provides significantly superior rate of first-line disease control with early MRD-negativity and a response with no contraindicated mutations.1,6

Sarah’s physician recommended ICLUSIG + chemotherapy after careful discussion with Sarah about managing treatment with her comorbidities.1,6
 
BCR::ABL1/ABL11IS=BCR::ABL1 International Scale; MRD=minimal residual disease; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; WBC=white blood cell.

View ICLUSIG efficacy data for Ph+ ALL

View ICLUSIG safety data for Ph+ ALL